Active Pharmaceutical Ingredients
Duloxetine SR (Sustained Release) Pellets are formulated to provide a controlled release of duloxetine hydrochloride, a serotonin-norepinephrine reuptake inhibitor (SNRI). They are primarily used in the treatment of major depressive disorder, generalized anxiety disorder, neuropathic pain, fibromyalgia, and chronic musculoskeletal pain. The SR formulation ensures prolonged therapeutic activity, reducing dosing frequency and improving patient compliance.
| Component | Function |
|---|---|
| Duloxetine Hydrochloride | Active Pharmaceutical Ingredient (API) |
| Sugar Spheres / MCC Spheres | Inert core or starter pellets |
| Hydroxypropyl Methylcellulose (HPMC) | Binder / Film former during layering |
| Talc / Colloidal Silicon Dioxide | Anti-adherent / Glidant |
| Ethylcellulose / Eudragit RS/RL | Sustained release polymer (controls drug release) |
| Triethyl Citrate / PEG 6000 | Plasticizer (for polymer coating) |
| Purified Water | Solvent (removed after processing) |
Outsourcing pellets through a trusted partner like Salius Pharma can be a strategic decision to save both time and resources, without compromising on quality or compliance. Instead, partnering with Salius Pharma—a leading distributor aligned with USFDA-approved and WHO-GMP-certified manufacturers in India—allows you to leverage high-quality products, seamless logistics, and professional support under one roof.
We ensure prompt and reliable shipping worldwide. Delivery times may vary depending on destination, order volume, and regulatory requirements.
Looking to source Duloxetine SR Pellets or other high-quality pharmaceutical pellet formulations?
Whether you need Active Pharmaceutical Ingredients (APIs), excipients, or regulatory support, our team is ready to provide reliable, compliant, and cost-effective solutions tailored to your market needs.
The contents of this page and any attachments are intended solely for the designated recipient(s) and may contain confidential and/or privileged information protected by law.
Any patented products are excluded from our offerings in regions where such patents are currently in force.
They are used in the treatment of depression, anxiety, neuropathic pain, and fibromyalgia.
Absolutely. They can be combined with other pellet types (e.g., immediate release or delayed release) in multi-unit pellet system (MUPS) capsules or tablets.
They comply with pharmacopeial guidelines (USP/EP/BP) and must meet ICH stability and cGMP manufacturing requirements.
We provide COA (Certificate of Analysis), MSDS (Material Safety Data Sheet), Stability Data, and necessary regulatory support documents.